- Home
- ARKO vs MNPR Comparison
ARKO vs MNPR Comparison
Compare ARKO & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARKO
- MNPR
- Stock Information
- Founded
- ARKO 1970
- MNPR 2014
- Country
- ARKO United States
- MNPR United States
- Employees
- ARKO N/A
- MNPR N/A
- Industry
- ARKO Oil Refining/Marketing
- MNPR Biotechnology: Pharmaceutical Preparations
- Sector
- ARKO Energy
- MNPR Health Care
- Exchange
- ARKO Nasdaq
- MNPR Nasdaq
- Market Cap
- ARKO 453.2M
- MNPR 390.5M
- IPO Year
- ARKO N/A
- MNPR 2019
- Fundamental
- Price
- ARKO $4.40
- MNPR $81.24
- Analyst Decision
- ARKO Buy
- MNPR Strong Buy
- Analyst Count
- ARKO 3
- MNPR 12
- Target Price
- ARKO $7.50
- MNPR $96.64
- AVG Volume (30 Days)
- ARKO 410.9K
- MNPR 84.9K
- Earning Date
- ARKO 11-05-2025
- MNPR 11-10-2025
- Dividend Yield
- ARKO 2.68%
- MNPR N/A
- EPS Growth
- ARKO N/A
- MNPR N/A
- EPS
- ARKO 0.08
- MNPR N/A
- Revenue
- ARKO $8,131,937,000.00
- MNPR N/A
- Revenue This Year
- ARKO N/A
- MNPR N/A
- Revenue Next Year
- ARKO N/A
- MNPR N/A
- P/E Ratio
- ARKO $56.02
- MNPR N/A
- Revenue Growth
- ARKO N/A
- MNPR N/A
- 52 Week Low
- ARKO $3.51
- MNPR $12.55
- 52 Week High
- ARKO $7.84
- MNPR $105.00
- Technical
- Relative Strength Index (RSI)
- ARKO 51.93
- MNPR 52.54
- Support Level
- ARKO $3.94
- MNPR $72.00
- Resistance Level
- ARKO $4.57
- MNPR $104.00
- Average True Range (ATR)
- ARKO 0.15
- MNPR 8.27
- MACD
- ARKO 0.07
- MNPR -3.08
- Stochastic Oscillator
- ARKO 80.23
- MNPR 28.87
About ARKO ARKO Corp.
ARKO Corp owns and operates convenience stores in the United States. Some of its regional store brands include Stop, Admiral, Apple Market, BreadBox, E-Z Mart, fas mart, Li'l Cricket, and Next Door Store. Its retail store offers hot food service, beverages, cigarettes & other tobacco products, candy, salty snacks, grocery, beer, and general merchandise. ARKO operates in four segments: Retail segment, Wholesale segment, fleet fueling segment, and GPM Petroleum segment. The company derives the majority of its revenue from retail and wholesale distribution of fuel.
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.